This patient is not breathing properly: is this COPD, heart failure, or neither?

References

• Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members.; Document Reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Pellicori P, Dierckx R. Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Fail Clin. 2014;10:511–523.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181–1196.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Cleland JG, Zhang J, et al. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther. 2016;30:599–609.
   PubMed Web of Science ®Google Scholar
• Disantostefano RL, Li H, Rubin DB, et al. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open. 2013;3(4):e001838.
   Web of Science ®Google Scholar
• Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–139.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective therapies. Jama. 2013;309:825–826.
   PubMed Web of Science ®Google Scholar
• Rodríguez LA, Wallander MA, Martín-Merino E, et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010;104:1691–1699.
   PubMed Web of Science ®Google Scholar
• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.
   PubMed Web of Science ®Google Scholar
• Kaszuba E, Odeberg H, Råstam L, et al. Heart failure and levels of other comorbidities in patients with chronic obstructive pulmonary disease in a Swedish population: a register-based study. BMC Res Notes. 2016;9:215.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106:249–256.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8:706–711.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–1894.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Niemeijer MN, van den Berg ME, et al. Chronic obstructive pulmonary disease and sudden cardiac death: the rotterdam study. Eur Heart J. 2015;36:1754–1761.
   PubMed Web of Science ®Google Scholar
• Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.
   PubMed Web of Science ®Google Scholar
• Jensen HH, Godtfredsen NS, Lange P, et al. Potential misclassification of causes of death from COPD. Eur Respir J. 2006;28:781–785.
   PubMed Web of Science ®Google Scholar
• Müllerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–1178.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, et al.; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333–339.
   PubMed Web of Science ®Google Scholar
• Zvezdin B, Milutinov S, Kojicic M, et al. postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136:376–380.
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62:411–415.
   PubMed Web of Science ®Google Scholar
• van den Berg ME, Stricker BH, Brusselle GG, et al. Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review. Trends Cardiovasc Med. 2016;26:606–613.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Anthonisen N, Coultas D, et al.; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693–718.
   PubMed Web of Science ®Google Scholar
• Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med. 2011;183:455–461.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582.
   PubMed Web of Science ®Google Scholar
• Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143:429–433.
   PubMed Web of Science ®Google Scholar
• Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure–COPD or congestion? Int J Cardiol. 2013;168:1910–1916.
   PubMed Web of Science ®Google Scholar
• Krahnke JS, Abraham WT, Adamson PB, et al.; Champion Trial Study Group. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. 2015;21:240–249.
   PubMed Web of Science ®Google Scholar
• Guder G, Rutten FH, Brenner S, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18:637–644.
   PubMed Web of Science ®Google Scholar
• Agostoni P, Bussotti M, Cattadori G, et al. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006;27:2538–2543.
   PubMed Web of Science ®Google Scholar
• Wasserman K, Zhang YY, Gitt A, et al. Lung function and exercise gas exchange in chronic heart failure. Circulation. 1997;96:2221–2227.
   PubMed Web of Science ®Google Scholar
• Olson TP, Johnson BD. Influence of cardiomegaly on disordered breathing during exercise in chronic heart failure. Eur J Heart Fail. 2011;13:311–318.
   PubMed Web of Science ®Google Scholar
• Daganou M, Dimopoulou I, Alivizatos PA, et al. Pulmonary function and respiratory muscle strength in chronic heart failure: comparison between ischaemic and idiopathic dilated cardiomyopathy. Heart. 1999;81:618–620.
   PubMed Web of Science ®Google Scholar
• Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179:509–516.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Zhang J, Pellicori P, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016;1:539–547.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Cleland JG. Heart failure with preserved ejection fraction. Clin Med (Lond). 2014 Dec;14(Suppl 6):s22–8.
   PubMedGoogle Scholar
• Van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18:242–252.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Cleland JG. Update on management of heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015;30:173–178.
   Web of Science ®Google Scholar
• Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. Eur Heart J. 2007;28:2539–2550.
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003;24:320–328.
   PubMed Web of Science ®Google Scholar
• Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014;63:407–416.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Kallvikbacka-Bennett A, Dierckx R, et al. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart. 2015;101:1149–1158.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Kallvikbacka-Bennett A, Khaleva O, et al. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Cardiovasc Imaging. 2014;30:69–79.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer MJ, Zuithoff NP, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007;9:651–659.
   PubMed Web of Science ®Google Scholar
• Nielsen LS, Svanegaard J, Klitgaard NA, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004;6:63–70.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kawayama T, Iwanaga T, et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med. 2009;48:503–512.
   PubMed Web of Science ®Google Scholar
• Kanat F, Vatansev H, Teke T. Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med. 2007;65:296–300.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, Goei D, Hoeks SE, et al. Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. Copd. 2010;7(1):70–75.
   PubMedGoogle Scholar
• Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173:744–750.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331–342.
   PubMed Web of Science ®Google Scholar
• Stamm JA, Belloli EA, Zhang Y, et al. Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction. Plos One. 2011;6:e27416.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Papacosta O, et al. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men-the british regional heart study. Thorax. 2016;71(6):526–534.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, et al.; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811–1821.
   PubMed Web of Science ®Google Scholar
• Regan EA, Lynch DA, Curran-Everett D, et al.; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and Radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015;175:1539–1549.
   PubMed Web of Science ®Google Scholar
• Townsend MC. Conflicting definitions of airways obstruction: drawing the line between normal and abnormal. Chest. 2007 Feb;131(2):335–336.
   PubMed Web of Science ®Google Scholar
• Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not <70%. Chest. 2007;131:349–355.
   PubMed Web of Science ®Google Scholar
• Georgiopoulou VV, Kalogeropoulos AP, Psaty BM, et al. Lung function and risk for heart failure among older adults: the Health ABC Study. Am J Med. 2011;124:334–341.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35:1628–1637.
   PubMed Web of Science ®Google Scholar
• Sabit R, Bolton CE, Fraser AG, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104:1171–1178.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371–1385.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Kallvikbacka-Bennett A, Zhang J, et al. Revisiting a classical clinical sign: jugular venous ultrasound. Int J Cardiol. 2014;170:364–370.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Goode KM, Nicholls R, et al. Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. Int J Cardiol. 2016;210:149–155.
   PubMed Web of Science ®Google Scholar
• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66:764–768.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Carubelli V, Zhang J, et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging. 2013;6:16–28.
   PubMed Web of Science ®Google Scholar
• Komajda M, Follath F, Swedberg K, et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euroheart failure survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–474.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlström U, Filippatos G, et al.; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808–817.
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818–824.
   PubMed Web of Science ®Google Scholar
• Witte KK, Clark AL. Beta-blockers and inspiratory pulmonary function in chronic heart failure. J Card Fail. 2005;11:112–116.
   PubMed Web of Science ®Google Scholar
• Düngen HD, Apostolovic S, Inkrot S, et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13:670–680.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684–690.
   PubMed Web of Science ®Google Scholar
• Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780–1787.
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Bmj. 2011;342:d2549.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880–887.
   PubMed Web of Science ®Google Scholar
• Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. Plos One. 2014;9:e113048.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554–2560.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
   PubMed Web of Science ®Google Scholar
• Sharma B, Goodwin JF. Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on Systolic and Diastolic Function of the Left Ventricle. Circulation. 1978;58:449–460.
   PubMed Web of Science ®Google Scholar
• Mifune J, Kuramoto K, Ueda K, et al. Hemodynamic effects of salbutamol, an oral long-acting beta-stimulant, in patients with congestive heart failure. Am Heart J. 1982;104:1011–1015.
   PubMed Web of Science ®Google Scholar
• Rojas-Reyes MX, García Morales OM, Dennis RJ, et al. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;6:CD008532. doi: 10.1002/14651858.CD008532.pub3.
   Google Scholar
• Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5:e009183.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826.
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964–1969.
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Curtis JR, et al.; ACQUIP Investigators. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J. 2004;148:915–920.
   PubMed Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68:48–56.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Bmj. 2011;342:d3215.
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7:CD009285. doi: 10.1002/14651858.CD009285.pub3.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama. 2008;300:1439–1450.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68:114–116.
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22:92–100.
   PubMedGoogle Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294.
   PubMed Web of Science ®Google Scholar
• Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981–989.
   PubMed Web of Science ®Google Scholar
• Van Riet EE, Hoes AW, Limburg A, et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16:772–777.
   PubMed Web of Science ®Google Scholar
• Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111–122.
   PubMed Web of Science ®Google Scholar
• Si R, Locantore N, Delafont B, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12:303–312.
   PubMedGoogle Scholar
• Pfeffer MA, Braunwald E. Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiol. 2016;1:7–8.
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al.; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Connett JE, Voelker H, et al. β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open. 2016;6(6):e012292.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chronic Obstr Pulm Dis. 2015;2:23–34.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671.
   PubMed Web of Science ®Google Scholar